U.S. Markets closed

Why Shareholders Should Vote for Bristol-Myers Celgene Deal: Jim Cramer

Katherine Ross

Jim Cramer thinks that Bristol-Myer's deal with Celgene is a positive thing, despite Starboard's resistance.